We conducted a systematic review on the performance of diagnostic tests for clinical and laboratory monitoring of HIVinfected adults in developing countries. Diagnostic test information collected from computerized databases, bibliographies and the Internet were categorized as clinical (non-laboratory patient information), immunologic (information from immunologic laboratory tests), or virologic (information from virologic laboratory tests). Of the 51 studies selected for the review 28 assessed immunologic tests, 12 virologic tests and seven clinical and immunologic tests. Methods of performance evaluation were primarily sensitivity and specificity for the clinical category and correlation coefficients for immunologic and virologic categories. In the clinical category, the majority of test performance measures was reported as >70% sensitive and >65% specific. In the immunologic category, correlation coefficients ranged from r = 0.54 to r = 0.99 for different CD4 count enumeration techniques, while correlation for CD4 and total lymphocyte counts was between r = 0.23 and r = 0.74. In the virologic category, correlation coefficients for different human immunodeficiency virus (HIV) ribonucleic acid (RNA) quantification techniques ranged from r = 0.54 to r = 0.90. Future research requires consensus on designing studies, and collecting and reporting data useful for decision-makers. We recommend classifying information into clinically relevant categories, using a consistent definition of disease across studies and providing measures of both association and accuracy.
Introduction
In developed countries, immunologic and virologic status of human immunod d deficiency virus (HIV)dinfected patients is monitored using laboratory markers. Cluster designation 4 (CD4) cell count and human immunodeficiency virus (HIV) ribonucleic acid (RNA) level (or viral load) have been shown to predict both clinical outcomes and disease prod d gression. [1] [2] [3] Past guidelines published by WHO also recommended the use of CD4 cell count and HIV RNA to monitor HIVdinfected individuals. 4, 5 As part of its "3dbyd5" initiative, WHO proposed a tiered patient monitoring framework with CD4 cell count at the district level and CD4 cell count and HIV RNA quantification at the regional level, but with neither compulsory for patient management (Table 1) . However, .587 ‫صفحة‬ ‫يف‬ ‫بالعربية‬ ‫امللخص‬ ‫عىل‬ ‫االطالع‬ ‫ميكن‬ these guidelines provide limited guidd d ance on other diagnostic tests to guide therapeutic decisiondmaking in HIV management. 6, 7 Our objective was to review the litd d erature on the performance of diagnostic tests for clinical and laboratory monitord d ing of HIVdinfected adults. We compiled relevant qualitative and quantitative information to make it accessible to a wide range of users and to identify key challenges regarding the method of HIVd related diagnostic test data collection and reporting in developing countries. 
Methods

Overview
Study Selection
We selected studies according to a priori inclusion and exclusion criteria ( Table 2) . Inclusion criteria were determined in two stages. Test performance evaluation was defined as sensitivity and/or specificd d ity as well as correlation coefficients. We considered assessment of instruments, equipment, or other technology used to perform the diagnostic tests as secondary criteria for study inclusion.
Exclusion criteria were also identid d fied in two stages. We assumed that the basic biologic and cellular mechanisms of HIV disease progression are similar ZDV = zidovudine. c In primary health care centers where laboratory facilities are not available or in the absence of laboratory-based haemoglobinometry, the WHO haemoglobin colour scale can be used together with clinical signs to evaluate anaemia (more information available from: www.who.int/bct/). d Scale-up of antiretroviral treatment under the "3 by 5" plan does not require uniform CD4 (cluster designation 4) testing availability but, because of the value of this test in patient monitoring, WHO will work with Member States to make this a reality. e EFV = efavirenz. EFV should not be given to women with childbearing potential unless adequate contraception is assured, nor to women in the first trimester of pregnancy. f FBC = full blood count. g ALT = amino alanine transferase. h Because of the cost and technical issues associated with viral load testing, this test is not currently recommended as part of the present treatment guidelines.
However, it is hoped that more cost-effective technologies will allow regional referral centers to acquire this capability given its utility in assessing treatment failure.
for all HIVdinfected individuals; bed d cause the relationship between CD4 cell count and HIV RNA has been shown to reflect disease progression rather than test performance, 1 we excluded studies solely on the association between these two measures.
Neither use nor type of treatment (e.g. antiretroviral therapy or opportud d nistic infection prophylaxis) was used as inclusion or exclusion criteria.
Data extraction
To integrate available information on diagnostic tests for monitoring HIV pad d tients into a format useful for decisiond making, we classified diagnostic test information from each study into three categories: (1) 
Description of included studies
The number of HIVdinfected subjects reported in each study ranged from 12 to 2777 (mean = 229.4, standard deviad d tion (SD) 413.0). Mean age ranged from 27.0 to 38.0 years. Weighting mean age by number of study subjects resulted in a weighted mean age of 32.9 years (SD 2.2 years); 35 studies did not report mean age. The percentage of males enrolled in each study ranged from 28.9% to 77.2%. In a weighted analysis, we deterd d mined that 51.4% (SD 2.4%) of study subjects were male; gender distribution was not reported in 31 studies. A description of included studies is shown in Table 3 . The majority of studd d ies included in our review assessed imd d munologic diagnostic tests only (28/51 or 55%) . Twelve of 51 (24%) studies assessed virologic tests only while seven (14%) evaluated both clinical and imd d munologic diagnostic tests. Nine of 51 (18%) measured diagnostic test perford d mance using sensitivity/specificity only, 28 (55%) via correlation coefficient only and 14 (28%) via both sensitivity/specid d ficity and correlation.
Clinical information
We classified nine of 51 studies in this category, with two reporting multiple results for a total of 12 entries (Table 4 (measures of accuracy); Fig. 1 and Fig. 2 (measures of association); all web verd d sion only, available from http://www. who.int/bulletin). Ten of the 12 entries examined the relationship between clinid d cal and immunologic tests; five of the ten evaluated CD4 or total lymphocyte counts only and a clinical staging or classification system only, and three of the ten compared the performance of various permutations of clinical and immunologic tests. Sensitivity of these 10 entries ranged from 29% when usd d ing oral candidiasis to predict CD4 cell counts <200 cells/mm³ to 96% when using clinical staging, total lymphocyte count and white blood cell count to predict CD4 cell count; specificity for these studies was 96% and 83%, respecd d tively. 17, 18 Four entries compared clinical staging to CD4 cell count as measured by flow cytometry and one examined clinid d cal staging and total lymphocyte count as measured by haematology analyser. Two of 12 entries compared clinical informad d tion and virologic information 19 as well as clinical and immunologic informad d tion and virologic information. 20 Two of 12 entries evaluated performance using measures of association.
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Immunologic information
We classified 39 of 51 studies in this category, with 14 of 39 reporting muld d tiple results for a total of 81 entries ( (28) a Percentages may not total 100% due to rounding. b Countries were assigned an income-level status (low, low-middle, middle-high, or high) based on gross national income per capita. 8 One study 13 was classified as both low and low-middle income. c An urban area was defined as a major city and/or the city's outlying areas. d Three studies [14] [15] [16] had study subjects who were both on and off antiretroviral therapy. reported only sensitivity/specificity, and 13 reported correlation coefficients and sensitivity/specificity. We found that studies assessing difd d ferent techniques for measuring CD4 cell count reported correlation coefficients ranging from r = 0.54 to r = 0.99. 21, 22 In the four studies examining enzyme imd d munoassay, correlations between CD4 cell count as measured by dualdplatform flow cytometry and enzyme immunod d assay were all r <0.70. 12, 21, 23, 24 When a blood fixative was employed using dualdplatform flow cytometry with pand d leucogating, correlations were r = 0.97 at day 0, r = 0.98 between days 0 and 3, and r = 0.92 between days 0 and 7.
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In our review, correlation between total lymphocyte and CD4 cell counts ranged from r = 0.23 to r = 0.74. 26, 27 Sensitivity when assessing CD4 cell count and total lymphocyte count ranged from 43% for a total lymphocyte count <1200 cells/mm³ to predict a CD4 cell count <200 cells/mm³ to 78% for a total lymd d phocyte count <1500 cells/mm³ to pred d dict a CD4 cell count <200 cells/mm³; specificity for these studies was 98% and 80%, respectively. 28, 29 For the 22 entries in which CD4 cell count served as the reference standard and for which sensitivity/specificity were reported, 18 and 2 entries reported a diseasedpresent status of CD4 count <200 cells/mm³ and <350 cells/mm³, respectively.
Virologic information
We classified 16 of 51 studies in this category, with five reporting results for multiple diagnostic tests, resulting in a total of 26 entries (Table 4 presents one measure of accuracy and Table 5 presents two measures of accuracy; Fig. 2 (measures of association) all web version only, available at http://www.who.int/ bulletin). Twentydone of 26 entries comd d pared HIV RNA quantification and viral activation markers or reverse transcriptase activity; the remaining five evaluated viral activation markers and clinical staging or immune activation markers (e.g. bd2 microglobulin, CD4 cell count). Fifteen entries evaluated HIVd1 infected study subjects with nondB subtypes, including CRF02_AG and subtypes A, C, D, and G in West Africa; A and D in East Africa; E in Southern Africa; and E in Southeast Asia. None of the studies included HIVd 2 infected study subjects. Sensitivity and specificity of diagnostic test performance were reported for only 4 entries, 19, 30 with the remainder reporting correlation coefficients.
Seventeen entries compared comd d monly used HIV RNA quantification techniques -reverse transcriptase polymerase chain reaction (RT PCR), branched deoxyribose nucleic acid (bDNA) and nucleic acid sequenced based amplification (NASBA). Correlad d tion coefficients for these, comparing both RT PCR and bDNA tests ranged from r = 0.54 to r = 0.90. 31, 32 Other virod d logic diagnostic tests examined included viral activation markers (p24 antigen assay) and reverse transcriptase activity. One study reported that concentration of p24 antigen <1500 fg/ml was 100% sensitive and 91% specific for HIVd1
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Discussion
Through a systematic review, we idend d tified, selected and critically evaluated 51 studies on clinical, immunologic and virologic strategies for monitoring HIVdinfected individuals in developing countries. In the studies we reviewed, over 90% were performed in African and Asian lower income countries and nearly 80% were conducted in urban areas. Monitoring strategies were assessed using a broad range of diagnostic tests, assays or staging systems.
Our review revealed that methods of performance evaluation varied widely across all three types of diagnostic test information categories (clinical, imd d munologic, virologic). For example, performance measures for "clinical ind d formation" were reported primarily as sensitivity and specificity. As expected, most studies reporting performance measures of a patient's clinical informad d tion focused on the relationship between a clinical staging or classification system and lymphocyte subsets (primarily CD4 count <200 cells/mm³). We found that the sensitivity of different clinical staging systems for CD4 cell count varied extend d sively (Fig. 3 , web version only, available from: http://www.who.int/bulletin).
In contrast, performance of diagnosd d tic tests using immunologic or virologic status was reported mainly as a correlad d tion coefficient. We found that correlad d tion coefficients ranged from r 2 = 0.29 to r 2 = 0.97 when comparing different techniques for enumerating CD4 cell count, suggesting relatively robust results among widely differing CD4 count enumeration technologies. 21, 22 However, when assessing the relationship between CD4 and total lymphocyte count, cord d relation coefficients ranged from r 2 = 0.05 to r 2 = 0.55, indicating less consistent findings and greater variation between these two tests. 26, 27 In the few studies reporting the sensitivity of a CD4 cell count enumeration technology, the disd d ease condition primarily was defined as CD4 count <200 cells/mm³. In these studies, sensitivity ranged from 29% to 96% 17, 18 and specificity from 55% to 98%. 28, 33 The performance of tests used to ascertain virologic status also was generd d ally reported as a correlation coefficient. Correlation coefficients ranged from r 2 = 0.29 to r 2 = 0.81 when we compared commonly used HIV RNA quantid d fication techniques. 31, 32 Correlations between different HIV RNA quantifid d cation techniques for nondB subtypes ranged mainly between r 2 = 0.49 and r 2 = 0.72. 34, 35 These results suggest rod d bust results among various HIV RNA quantification techniques for HIVd1 B and nondB subtypes. However, due to lack of information on HIVd2dinfected subjects, the performance of these tests in such patients is unknown. We idend d tified only one study examining the accuracy of viral activation markers for HIV RNA. 30 Our review had several limitations. We confined our study selection to artid d cles and conferences that were published and/or electronically available, which likely limited incorporation of the most updtoddate data. We also encountered a number of specific challenges in synd d thesizing this body of information. For example, no universal gold standard has been explicitly defined for monitoring HIVdinfected individuals, thereby makd d ing identification of the gold standard or reference standard for each study uncertain. The definition of disease and the methods used to assess diagnostic test performance were not consistent across studies. Therefore, we did not evaluate study quality to assess reliability and validity and could not account for bias, reporting error and other methd d odological limitations of the individual studies.
11 While measures of association, such as correlation coefficients, provide researchers with information on the strength of a relationship between two diagnostic tests, they do not provide information that can more easily be translated into clinical decisiondmaking as with measures such as sensitivity and specificity. This is particularly relevant for HIV markers evaluated on a continud d ous scale, where sensitivity and specificity can be used to identify critical clinical thresholds when providing antiretrovid d ral therapy or opportunistic infection prophylaxis. Lastly, we did not examine reported assay, instrument and persond d nel costs or include other biochemical parameters important in the followdup of HIVdinfected individuals receiving treatment, 36 as they were beyond the scope of this study.
While HIV care providers in develd d oping countries are working to improve laboratory capacity, key issues, such as where future studies might be conducted (e.g. urban versus rural locales) or the methods used to evaluate diagnostic test performance, have not been add d dressed. [37] [38] [39] [40] In particular, complete and transparent reporting of participants, test methods, statistical methods, test results and test estimates -as outlined in The Standards for Reporting of Diagnostic Accuracy (STARD) Initiative 11 -will play a major role in improving how diagnostic test data are collected and reported. Addressing these issues can provide important information that will assist programme planners and policyd makers in better understanding how diagnostic tests can be used to assess, for example, populationdlevel antiretrod d viral resistance patterns and HIV RNA distributions. On an individual level, this information can aid in determining not only which diagnostic tests should be used to monitor patients, but also which tests should be employed to inid d tiate HIV management interventions. For example, whether a patient's clinical information is an appropriate diagnostic tool to initiate opportunistic infection prophylaxis and/or antiretroviral therapy will depend on formal analysis that cond d siders the benefits of treating patients with true positive results as well as the consequences of not treating patients who need treatment (false negatives) and treating patients who do not need treatment (false positives).
Conclusion
We conclude that the broad range of diagnostic tests, the instruments and techniques used to conduct the tests, and the heterogeneity of their reported performance suggest a need for consensus among the research community on how to design studies, and collect and report data in a format that is most useful for decisiondmakers in developing countries. We recommend the following actions that are critical to successfully scaling up HIV treatment and monitoring efforts 
Call for papers -Bulletin theme issue on "health and foreign policy"
The Bulletin welcomes submissions on the topic of "health and foreign policy" for a theme issue of the Bulletin to be published in March 2007. Public health has become more important to the making and implementing of foreign policy over the past decade. Such explicit links have created both opportunities and challenges for people working in health protection and promotion. We are seeking papers on the historical, theoretical, and practical aspects of pursuing health as a foreign policy objective, and are particularly interested in research or policy and practice papers that provide developing country perspectives on the relationship between health and foreign policy. Papers that use examples or case studies to illustrate how foreign policy actions, instruments, or processes, constitute a determinant of health outcomes are also welcome. Papers submitted will be subject to the Bulletin's usual peer review process, and should be written in accordance with the Guidelines for Contributors, available from http://who. int/bulletin/en. The deadline for submission is 1 October 2006.
Public Health Reviews
April D Kimmel et al. 1996;195:103-12. c Tugume SB, Otim SW, Atwline D, Okiro J, Kityo C, Mugyenyi PN, et al. Inexpensive CD4 lymphocyte subset estimation by dual platform (dp) CD45 assisted panleucogating methoc using afford monoclonal antibodies [Abstract
Diagnostic tests in HIV management
Public Health Reviews
Diagnostic tests in HIV management April D Kimmel et al. 
